Journal: Scientific Reports

Article Title: Neuronal morphology and synaptic input patterns of neurons in the intermediate nucleus of the lateral lemniscus of gerbils

doi: 10.1038/s41598-023-41180-8

Figure Lengend Snippet: Primary antibodies used for histology.

Article Snippet: MAP2 , Chicken , Polyclonal , AMCA , 1:1000 , OriGene , TA336617.

Techniques:

Journal: Scientific Reports

Article Title: Neuronal morphology and synaptic input patterns of neurons in the intermediate nucleus of the lateral lemniscus of gerbils

doi: 10.1038/s41598-023-41180-8

Figure Lengend Snippet: Position and transmitter content of nuclei in the lateral lemniscus. ( a ) Nissl staining of the lateral lemnisicus and inferior colliculus. Black circle indicates position of the DNLL, magenta circle the position of the INLL and pink square the position of the VNLL. Scale bar equals 1 mm. ( b ) GABA (green) and glycine (red) immunofluorescence in the DNLL, INLL and VNLL (from left to right). Scale bare equals 100 µm. ( c ) Co-labelling of MAP2 (blue), GABA (green) and glycine (red) immunofluorescence in the DNLL, INLL, VNLL and MNTB as indicated. Triple staining is given on the left, the single fluorescence of each channel is given in black in the indicated order: MAP-2, GABA and glycine. Scale bar equals 50 µm.

Article Snippet: MAP2 , Chicken , Polyclonal , AMCA , 1:1000 , OriGene , TA336617.

Techniques: Staining, Immunofluorescence, Fluorescence

Journal: Molecular Psychiatry

Article Title: A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome

doi: 10.1038/s41380-020-0659-y

Figure Lengend Snippet: a IHC for Shank2 (green), Vglut1 (red), MAP2 (magenta) (scale bar = 5 µm), western blot analysis for all different treatment regimens (CRH; the CRHR1 blocker NBI30775; the corticosterone receptor blocker RU38486; and BDNF) and the relative quantification. b IHC for Shank2 (green), Vglut1 (red), MAP2 (magenta) and CRHR1 (white) with colocalization and trilocalization analysis (scale bar = 5 µm). c IHC for phospho-NF-κB p65 (green, scale bar = 5 μm) and the relative quantification of the signal within the nuclear compartment. d IHC for phospho-IKB-α and the relative quantification of the signal within the cytosolic compartment. e IHC for and compartment analysis of p65. f IHC (left panel) for Shank2 (green), Vglut1 (red), MAP2 (magenta) (scale bar = 5 µm), WB of BDNF (right panel) for all different treatment regimens blocking the NF-κB pathway (JSH (the translocation blocker JSH- 23); SC (the IKK-β inhibitor SC-514); and LAC (the NF-κB activation blocker lactacystin)) and the relative quantification. g IHC for ATG5, immunoblot analysis of h BCN-1, i LC3, and j Lamp-2 and the relative quantification normalized to β-actin. k TEM of acquired synapses after 15 min of CRH treatment (arrows indicate membrane-associated vesicles (scale bar = 0.5 µm)) and the relative quantification of docked vesicles and multivesicular bodies (MVBs)/synapses (a two-tailed unpaired T -test was used). l Quantification of the number of excitatory synapses (left) by IHC and WB analysis of BDNF expression (right) after treatment with 100 nM CRH for 30 min and Leupeptin hemisulfate + 5 μM E64 (CRH++) compared with control treatment. N = 3–5; the error bars represent the SEMs; one-way ANOVA and Bonferroni’s post hoc comparison test were performed (* P ≤ 0.05, ** P ≤ 0.005, *** P ≤ 0.0005, **** P ≤ 0.0001).

Article Snippet: The following primary antibodies were purchased from commercial suppliers: Vglut1 (1:500, Synaptic Systems GmbH, #135304), Gephyrin (1:500, Synaptic Systems GmbH, #147003), Vgat (1:500, Synaptic Systems GmbH, #131011), Iba1 (1:250, Wako Chemical GmbH, #NCNP24), GFAP (1:500, Sigma-Aldrich, #G3893 ) , NeuN (1:1000, Millipore, #MAB377), C1q (1:1000, Abcam, #182451), CRH (1:1000, Abcam, #8901), p62 (1:500, Abcam, #56416), Map2 (1:500, EnCor Biotechnology Inc., #CPCA-MAP2), Synaptotagmin-1 (1:500, Synaptic Systems, #105311C5), ATG5 (Abcam, #AB108327), NF-κB p65 (1:500, Santa Cruz, #SC8008), phospho-NF-κB (Thr435) (1:500, Thermo Fisher Scientific, #PA5–37724), phospho-IκBα (Ser32) (1:500, Cell Signaling, #2859), CRHR1 (1:500, Everest Biotech, #EB08035), and ChAT (1:250, Synaptic System, #297015).

Techniques: Western Blot, Blocking Assay, Translocation Assay, Activation Assay, Two Tailed Test, Expressing